Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors-Reference-Cited by-同舟云学术

Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors

Published:2022-05-30 Issue:4 Volume:32 Page:299-301
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Rodríguez Castells Marta,Galisteo Lencastre Veiga Carlos,Fernández-Morales Luis Antonio,Ejarque Martínez Clara,Soriano Sánchez Sandra,López Zurita Natalia,Climent Vicente Carla,Andreu Cobo Pablo,Sierra Boadas Marina,García García Yolanda,Seguí Palmer Miquel Àngel

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference10 articles.

1. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.;Ascierto;Lancet Oncol,2016

2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.;Dummer;Lancet Oncol,2018

3. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.;Kim;Cancer Chemother Pharmacol,2019

4. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy.;Hengstman;Ann Rheum Dis,2006

5. Secondary cardiac involvement in anti-SRP-antibody-positive myopathy: an 87-year-old woman with heart failure symptoms as the first clinical presentation.;Hara;BMC Neurol,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dabrafenib/trametinib;Reactions Weekly;2022-07